Skip to main content
. Author manuscript; available in PMC: 2021 Jul 28.
Published in final edited form as: Clin Chem Lab Med. 2020 Jul 28;58(8):1214–1222. doi: 10.1515/cclm-2019-1172

Figure 4. Effect of treatment modalities on the difference of BCR-ABL1 IS between specimens.

Figure 4

(A, B) Differences of BCR-ABL1 IS between BM and PB at early time points of TKI treatment (3–9 months, left) differ from that observed in long-term follow-up (≥12 months, right) (A); effect on the distribution of MR classification (B). (C, D) A Sankey diagram of paired samples with DMR (≥MR4) in at least one specimen for patients receiving imatinib (n = 134, C) or other TKI (n = 29, D). **p < 0.01, ***p < 0.001. BM, bone marrow; DMR, deep molecular response; PB, peripheral blood; MR, molecular response; MMR, major molecular response; TKI, tyrosine kinase inhibitor.